The results of this study indicated that PPARD rs2016520 and rs2267668 polymorphisms are not associated with any of the metabolic-related diseases including obesity, dyslipidemia, hyperhomocysteinemia, hyperuricemia, hypertension, T2DM and CAD. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.